PubMed ID:
19458364
Public Release Type:
Journal
Publication Year: 2009
Affiliation: University of Iowa College of Medicine and the Veterans Affairs Medical Center, Iowa City, IA 52242-1081, USA. bradley-dixon@uiowa.edu
DOI:
https://doi.org/10.1056/NEJMoa0805840
Authors:
Greene T,
Greene T,
Liu A,
Adams S,
Allon M,
Allon M,
Banqero A,
Beck G,
Beck GJ,
Berkoben M,
Berkowitz A,
Besarab A,
Bi S,
Braden G,
Braden GL,
Cantaffa T,
Casey B,
Chertow G,
Clagett P,
Cotton J Jr,
Cotton JR Jr,
Coyne D,
Creaghan R,
Cyr-Alves H,
DAC Study Group,
Darras F,
Davidson I,
Davidson IJ,
Deeb J,
Delmez J,
Delmez JA,
Dember L,
Dember LM,
Diener-West M,
Dixon B,
Dixon BS,
Dolmatch B,
DuPage K,
Egbert P,
Feldman H,
Feldman HI,
Fenves A,
Fenves AZ,
Franzwa B,
Freedman S,
Freiberger W,
Garrison K,
Gassman J,
Gassman JJ,
Gitter K,
Grant C,
Greenberg A,
Greenberg A,
Hawley M,
Himmelfarb J,
Himmelfarb J,
Hoballah J,
Holmberg E,
Holmes D,
Hu B,
Hu B,
Hunsicker L,
Husband E,
Ikizler A,
Ikizler TA,
Jenkins V,
Kane J,
Katz D,
Kaufman J,
Kaufman JS,
Ketel B,
Kovalik E,
Kresowik T,
Kusek J,
Kusek JW,
Lauer A,
Lawson J,
Lawson JH,
LeSage P,
Levin N,
Lightfoot T,
Littmon L,
Lluka B,
Lockhart M,
Louis T,
Lucas B Jr,
Martin K,
Martin KJ,
McClellan W,
McNeil J,
McNeil JW,
Meyers C,
Meyers CM,
Middleton J,
Nathan R,
Newsome J,
Pearl G,
Pflederer T,
Pyszka L,
Quarles A,
Quinones H,
Radeva M,
Radeva MK,
Rahman A,
Rahman A,
Rayhill S,
Reyes B,
Rhodes S,
Robbin M,
Rothstein M,
Ryan M,
Santos R,
Saxena R,
Schmitz P,
Schumm D,
Schwab S,
Sharp W,
Shenoy S,
Slavin M,
Stehman-Breen C,
Thompson J,
Toto R,
Tuason L,
Valentine J,
Vazquez M,
Vazquez MA,
Violette R,
Wedeking D,
Weiss B,
Welch K,
Whiting J,
Whiting JF,
Windus D,
Work J,
Wounded Arrow A,
Wu Y,
Ying C
Studies:
Dialysis Access Consortium
,
Dialysis Access Consortium GRAFT
Arteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascular antiproliferative activity.